Prometheus Biosciences Stock Retained Earnings
| RXDXDelisted Stock | USD 199.92 0.24 0.12% |
Prometheus Biosciences fundamentals help investors to digest information that contributes to Prometheus Biosciences' financial success or failures. It also enables traders to predict the movement of Prometheus Stock. The fundamental analysis module provides a way to measure Prometheus Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Prometheus Biosciences stock.
Prometheus |
Prometheus Biosciences Company Retained Earnings Analysis
Prometheus Biosciences' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Prometheus Biosciences Retained Earnings | (331.09 M) |
Most of Prometheus Biosciences' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prometheus Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Prometheus Biosciences has a Retained Earnings of (331.09 Million). This is 135.55% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 103.55% higher than that of the company.
Prometheus Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prometheus Biosciences' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prometheus Biosciences could also be used in its relative valuation, which is a method of valuing Prometheus Biosciences by comparing valuation metrics of similar companies.Prometheus Biosciences is currently under evaluation in retained earnings category among its peers.
Prometheus Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (40.65) % | |||
| Current Valuation | 4.39 B | |||
| Shares Outstanding | 47.81 M | |||
| Shares Owned By Insiders | 16.61 % | |||
| Shares Owned By Institutions | 81.01 % | |||
| Number Of Shares Shorted | 4.68 M | |||
| Price To Earning | (5.66) X | |||
| Price To Book | 19.88 X | |||
| Price To Sales | 627.82 X | |||
| Revenue | 6.81 M | |||
| Gross Profit | (106.04 M) | |||
| EBITDA | (145.78 M) | |||
| Net Income | (141.75 M) | |||
| Cash And Equivalents | 95.96 M | |||
| Cash Per Share | 2.35 X | |||
| Total Debt | 14.76 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 13.32 X | |||
| Book Value Per Share | 14.62 X | |||
| Cash Flow From Operations | (123.25 M) | |||
| Short Ratio | 3.97 X | |||
| Earnings Per Share | (3.54) X | |||
| Target Price | 190.0 | |||
| Number Of Employees | 97 | |||
| Beta | -0.49 | |||
| Market Capitalization | 9.56 B | |||
| Total Asset | 740.77 M | |||
| Retained Earnings | (331.09 M) | |||
| Working Capital | 685.33 M | |||
| Current Asset | 135.99 M | |||
| Current Liabilities | 24.54 M | |||
| Net Asset | 740.77 M |
About Prometheus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prometheus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prometheus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prometheus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |